Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced the launch of Time To GoTM today, a multi-channel educational camp

Endpoints News — Genentech touts Tecentriq combo data in liver cancer; Rep. Frank Pallone criticizes noncompliance with trial records law

Physician Webinars - Advanced Urology

Welcome to Urovant Sciences Medical Affairs

Uriless - Help Reduce the Symptoms of Overactive Bladder and Urine Incontinence

Urovant Sciences® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season

TruBlue Total House Care - Products, Competitors, Financials, Employees, Headquarters Locations

Six United Way programs that support students - United Way Alberta Capital Region

ICS 2022 Abstract #6 Efficacy and Safety of a Novel Gene Therapy (URO-902; pVAX/hSlo) in Female Patients With Overactive Bladder Syndrome and Urgency Urinary Incontinence: Results From a Phase 2a Trial

UBC Press Our Chemical Selves - Gender, Toxics, and Environmental Health, Edited by Dayna Nadine Scott